A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell ...

LARKSPUR, CA, USA I April 14, 2025 I Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of ...

In vivo influenza protection was achieved at a significantly lower antibody dose with intranasal compared to systemic administration In contrast to what is observed with systemic administration ...

On Crowncast, Enrico Pesenti explains how cancer drug resistance forms and how advanced technologies are helping researchers ...

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

TG Therapeutics (TGTX) announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

In March 2025, AbViro LLC announced a phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare ...